LncRNA PCAT-1对鼻咽癌细胞生物学行为及化疗敏感性的影响

doi:10.6040/j.issn.1673-3770.0.2024.154

摘要/Abstract

摘要： 目的探讨长链非编码RNA转录产物1(long non-coding RNA Prostate cancer associated transcript-1, lncRNA PCAT-1)对鼻咽癌HK-1细胞生物学行为及化疗敏感性的影响。方法实时定量 PCR(Real-time quantitative PCR, RT-qPCR)检测LncRNA PCAT-1在不同鼻咽癌细胞株中的表达,CCK8、transwell、流式细胞术检测过表达/干扰LncRNA PCAT-1的HK -1细胞增殖、迁移、侵袭、凋亡的变化,蛋白免疫印记(Western blot, WB)检测上皮间质转化(epithelial-mesenchymal transition, EMT)通路相关蛋白的表达,细胞增殖实验检测5-FU及DDP的半数抑制率( median inhibition concentration, IC50)变化。结果 LncRNA PCAT-1在HK-1细胞株中表达升高。过表达LncRNA PCAT-1后,HK-1细胞的增殖、迁移、侵袭显著增加,而凋亡减少;E-cadherin蛋白表达水平显著降低,vimentin和N-cadherin蛋白表达水平显著升高;过表达后HK-1细胞对5-FU及DDP的IC50升高,细胞克隆数增加。干扰LncRNA PCAT-1后则相反,HK-1细胞增殖、迁移、侵袭显著降低,而凋亡增加;E-cadherin蛋白表达量显著升高,vimentin和N-cadherin蛋白表达水平显著降低;干扰后HK-1细胞对5-FU及DDP的IC50降低,细胞克隆数减少;差异均有显著性意义(P<0.05)。结论 lncRNA PCAT-1通过EMT途径来调控鼻咽癌HK-1细胞的生物学行为,并降低细胞对5-FU和DDP的药物敏感性。

关键词: 鼻咽癌细胞, 长链非编码RNA转录产物1, 上皮间质转化, 化疗敏感性

Abstract: Objective To investigate the effect of(long non-coding RNA Prostate cancer associated transcript-1, lncRNA PCAT-1)on the biological behaviour and chemosensitivity of nasopharyngeal carcinoma HK-1 cells. Methods Real-time quantitative PCR(RT-qPCR)was used to detect the expression of LncRNA PCAT-1 in different nasopharyngeal carcinoma cell lines. CCK8, Transwell, and flow cytometry were used to detect changes in cell proliferation, migration, invasion, and apoptosis of HK-1 cells overexpressing/interfering with LncRNA PCAT-1. Western blot(WB)was used to detect the expression of proteins associated with the epithelial-mesenchymal transition(EMT)pathway. Cell proliferation experiments were used to detect changes in the median inhibition concentration(IC50 )of 5-FU and DDP. Results The expression of LncRNA PCAT-1 was increased in nasopharyngeal carcinoma cell lines. Overexpression of LncRNA PCAT-1 significantly increased the proliferation, migration, and invasion of HK-1 cells, while decreasing apoptosis; the expression level of E-cadherin protein significantly decreased, while the expression levels of vimentin and N-cadherin proteins were significantly increased. Overexpression also increased the IC50 of HK-1 cells against 5-FU and DDP and the number of cell clones. Interference with LncRNA PCAT-1, on the contrary, led to reduced proliferation, migration, and invasion, with increased apoptosis in HK-1 cells. The expression level of E-cadherin protein significantly increased, while the expression levels of vimentin and N-cadherin proteins significantly decreased. After interference, the IC50 of HK-1 cells against 5-FU and DDP decreased, and the number of cell clones reduced.All differences were statistically significant(P<0.05). Conclusion LncRNA PCAT-1 regulates the biological behavior of HK-1 nasopharyngeal carcinoma cells through the EMT pathway and reduces their drug sensitivity to 5-FU and DDP.

Key words: Nasopharyngeal carcinoma cells, LncRNA PCAT-1, Epithelial-mesenchymal transition, EMT, Chemotherapy sensitivity

中图分类号:

R739.6

张茂华,魏日富,朱忠寿,刘平,高尚,李慧凤. LncRNA PCAT-1对鼻咽癌细胞生物学行为及化疗敏感性的影响[J]. 山东大学耳鼻喉眼学报, 2025, 39(1): 68-76.

ZHANG Maohua, WEI Rifu, ZHU Zhongshou, LIU Ping, GAO Shang, LI Huifeng. Effect of LncRNA PCAT-1 on the biological behaviour and chemosensitivity of nasopharyngeal carcinoma cells[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(1): 68-76.

参考文献

[1] Wang YA, Yan QJ, Mo YZ, et al. Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop[J]. Mol Cancer, 2022, 21(1): 62. doi:10.1186/s12943-022-01502-2
[2] Zhou C, Shen GW, Yang F, et al. Loss of AKR1C1 is a good prognostic factor in advanced NPC cases and increases chemosensitivity to cisplatin in NPC cells[J]. J Cell Mol Med, 2020, 24(11): 6438-6447. doi:10.1111/jcmm.15291
[3] Chen YP, Chan ATC, Le QT, et al. Nasopharyngeal carcinoma[J]. Lancet, 2019, 394(10192): 64-80. doi:10.1016/s0140-6736(19)30956-0
[4] Ruiz-Orera J, Messeguer X, Subirana JA, et al. Long non-coding RNAs as a source of new peptides[J]. Elife, 2014, 3: e03523. doi:10.7554/eLife.03523
[5] Discrimination negatively impacts minorities' cancer outcomes[J]. Cancer Discov, 2023, 13(12): OF3. doi:10.1158/2159-8290.CD-NB2023-0076
[6] Akhgari H, Shokri N, Dehghanzadeh P, et al. Expression pattern of PCAT1, PCAT2, and PCAT5 lncRNAs and their value as diagnostic biomarkers in patients with gastric cancer[J]. Pathol Res Pract, 2023, 248: 154654. doi:10.1016/j.prp.2023.154654
[7] Domvri K, Petanidis S, Anestakis D, et al. Exosomal lncRNA PCAT-1 promotes Kras-associated chemoresistance via immunosuppressive miR-182/miR-217 signaling and p27/CDK6 regulation[J]. Oncotarget, 2020, 11(29): 2847-2862. doi:10.18632/oncotarget.27675
[8] Chen YP, Chan ATC, Le QT, et al. Nasopharyngeal carcinoma[J]. Lancet, 2019, 394(10192): 64-80. doi:10.1016/S0140-6736(19)30956-0
[9] Yao F, Huang XY, Xie ZF, et al. LINC02418 upregulates EPHA2 by competitively sponging miR-372-3p to promote 5-Fu/DDP chemoresistance in colorectal cancer[J]. Carcinogenesis, 2022, 43(9): 895-907. doi:10.1093/carcin/bgac065
[10] Zhou DN, Ye CS, Pan ZY, et al. SATB1 knockdown inhibits proliferation and invasion and decreases chemoradiation resistance in nasopharyngeal carcinoma cells by reversing EMT and suppressing MMP-9[J]. Int J Med Sci, 2021, 18(1): 42-52. doi:10.7150/ijms.49792
[11] Huang J, Deng GR, Liu TM, et al. Long noncoding RNA PCAT-1 acts as an oncogene in osteosarcoma by reducing p21 levels[J]. Biochem Biophys Res Commun, 2018, 495(4): 2622-2629. doi:10.1016/j.bbrc.2017.12.157
[12] Cui WC, Wu YF, Qu HM. Up-regulation of long non-coding RNA PCAT-1 correlates with tumor progression and poor prognosis in gastric cancer[J]. Eur Rev Med Pharmacol Sci, 2017, 21(13): 3021-3027
[13] Shi WH, Wu QQ, Li SQ, et al. Upregulation of the long noncoding RNA PCAT-1 correlates with advanced clinical stage and poor prognosis in esophageal squamous carcinoma[J]. Tumour Biol, 2015, 36(4): 2501-2507. doi:10.1007/s13277-014-2863-3
[14] Xiong TF, Li JF, Chen FF, et al. PCAT-1: a novel oncogenic long non-coding RNA in human cancers[J]. Int J Biol Sci, 2019, 15(4): 847-856. doi:10.7150/ijbs.30970
[15] Prensner JR, Chen W, Iyer MK, et al. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer[J]. Cancer Res, 2014, 74(6): 1651-1660. doi:10.1158/0008-5472.CAN-13-3159
[16] Zhang DY, Cao JY, Zhong QL, et al. Long noncoding RNA PCAT-1 promotes invasion and metastasis via the miR-129-5p-HMGB1 signaling pathway in hepatocellular carcinoma[J]. Biomedecine Pharmacother, 2017, 95: 1187-1193. doi:10.1016/j.biopha.2017.09.045
[17] Yadav A, Biswas T, Praveen A, et al. Targeting MALAT1 augments sensitivity to PARP inhibition by impairing homologous recombination in prostate cancer[J]. Cancer Res Commun, 2023, 3(10): 2044-2061. doi:10.1158/2767-9764.CRC-23-0089
[18] Wang SJ, Liu C, Lei Q, et al. Relationship between long non-coding RNA PCAT-1 expression and gefitinib resistance in non-small-cell lung cancer cells[J]. Respir Res, 2021, 22(1): 146. doi:10.1186/s12931-021-01719-7
[19] Domvri K, Petanidis S, Anestakis D, et al. Exosomal lncRNA PCAT-1 promotes Kras-associated chemoresistance via immunosuppressive miR-182/miR-217 signaling and p27/CDK6 regulation[J]. Oncotarget, 2020, 11(29): 2847-2862. doi:10.18632/oncotarget.27675
[20] Shen XJ, Shen P, Yang Q, et al. Knockdown of long non-coding RNA pcat-1 inhibits myeloma cell growth and drug resistance via p38 and jnk mapk pathways[J]. J Cancer, 2019, 10(26): 6502-6510. doi:10.7150/jca.35098
[21] Guo JW, Jin D, Wu Y, et al. The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells[J]. eBioMedicine, 2018, 35: 204-221. doi:10.1016/j.ebiom.2018.08.001
[22] Shao QQ, Zhang P, Ma YY, et al. MicroRNA-139-5p affects cisplatin sensitivity in human nasopharyngeal carcinoma cells by regulating the epithelial-to-mesenchymal transition[J]. Gene, 2018, 652: 48-58. doi:10.1016/j.gene.2018.02.003
[23] Zhang P, Lu XY, Shi ZF, et al. MiR-205-5p regulates epithelial-mesenchymal transition by targeting PTEN via PI3K/AKT signaling pathway in cisplatin-resistant nasopharyngeal carcinoma cells[J]. Gene, 2019, 710: 103-113. doi:10.1016/j.gene.2019.05.058
[24] Lin XJ, He CL, Sun T, et al. Hsa-miR-485-5p reverses epithelial to mesenchymal transition and promotes cisplatin-induced cell death by targeting PAK1 in oral tongue squamous cell carcinoma[J]. Int J Mol Med, 2017, 40(1): 83-89. doi:10.3892/ijmm.2017.2992
[25] Zhang P, Liu H, Xia F, et al. Epithelial-mesenchymal transition is necessary for acquired resistance to cisplatin and increases the metastatic potential of nasopharyngeal carcinoma cells[J]. Int J Mol Med, 2014, 33(1): 151-159. doi:10.3892/ijmm.2013.1538

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed